NB 001
Alternative Names: Herpes labialis therapy - BlueWillow Biologics; NanoHPX; NB-001Latest Information Update: 09 May 2018
At a glance
- Originator NanoBio Corporation
- Class Antivirals; Skin disorder therapies
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Herpes labialis
Most Recent Events
- 07 May 2018 NanoBio Corporation is now called BlueWillow Biologics
- 07 Nov 2012 NanoBio initiates a phase III trial for recurrent Herpes labialis in USA (NCT01695187)
- 23 Jan 2012 NanoBio Corporation has completed a pivotal phase III trial for recurrent Herpes labialis in the US (NCT01321359)